Results 251 to 260 of about 736,547 (297)
Some of the next articles are maybe not open access.

ATP-stimulated ANP release through P1 receptor subtype

Regulatory Peptides, 2005
Extracellular ATP acts as a local regulator of physiological functions in the cardiovascular system via P1 and P2 receptors. However, little is known about the effect of ATP on the release of atrial natriuretic peptide (ANP) secretion. The purpose of this study was to investigate the effects of extracellular ATP on atrial hemodynamics and ANP release ...
Chunhua, Cao   +4 more
openaire   +2 more sources

Impact of Ectoenzymes on P2 and P1 Receptor Signaling

2011
P2 receptors that are activated by extracellular nucleotides (e.g., ATP, ADP, UTP, UDP, Ap(n)A) and P1 receptors activated by adenosine control a diversity of biological processes. The activation of these receptors is tightly regulated by ectoenzymes that metabolize their ligands.
Filip, Kukulski   +2 more
openaire   +2 more sources

Purinergic receptors in microglia: Functional modal shifts of microglia mediated by P2 and P1 receptors

Glia, 2012
AbstractMicroglia are sensitive to environmental changes and are immediately transformed into several phenotypes. For such dynamic “modal shifts”, purinergic receptors have central roles. When microglia sense ATP/ADP leaked from injured cells by P2Y12 receptors, they are transformed into a moving phenotype, showing process extension and migration ...
Schuichi, Koizumi   +3 more
openaire   +2 more sources

P1 and P2 Receptors in Platelets

2001
Because of the importance of platelets in haemostasis and thrombosis, these cell fragments have been extensively studied for many years and the existence of receptors for adenosine and adenine nucleotides on platelets has been recognised since the early 1960s.
openaire   +1 more source

Modulating P1 Adenosine Receptors in Disease Progression of SOD1G93A Mutant Mice

Neurochemical Research, 2019
Amyotrophic lateral sclerosis (ALS) is a fatal progressing neurodegenerative disease; to date, despite the intense research effort, only two therapeutic options, with very limited effects, are available. The purinergic system has been indicated as a possible new therapeutic target for ALS, but the results are often contradictory and generally confused.
Monica Armida   +6 more
openaire   +2 more sources

P1 and P2 receptors in cell growth and differentiation

Drug Development Research, 1996
Besides their well-established roles as short-term neurotransmitters, nucleotides and nucleosides are also potent regulators of cell growth and differentiation. Compelling evidence obtained on neural, immune, cardiovascular and respiratory system cells, as well as on many other cell types, suggests that these compounds may act as physiological ...
openaire   +2 more sources

Cancer immunomodulation by carbohydrate ligands for the lymphocyte receptor NKR-P1.

International Journal of Oncology, 2000
Natural killer (NK) and T cells express a superfamily of proteins with structural features of C-type lectins. Recombinantly prepared soluble form of rat NKR-P1 (CD161) recognized carbohydrate GalNac and GlcNac moieties. Ganglioside GM2 and heparin related-IS oligosaccharides representing the high affinity ligands for this receptor, increased the ...
M, Pospisil   +6 more
openaire   +2 more sources

P1 and P2 Receptors in the Renal System

2001
Modulation of the function of excretory organs by purine receptors is an ancient regulatory strategy adopted early in the course of vertebrate evolution. For instance, in the shark rectal gland, an excretory organ that evolved more than 400 million years ago, primordial adenosine receptors strongly influence the rate of sodium chloride transport and ...
openaire   +1 more source

Activation of the mouse heart adenosine 5',5'''-P1-P4-tetraphosphate receptor

Biochemistry, 1993
We have previously demonstrated that mouse brain membrane fractions have a specific, saturable receptor for diadenylated nucleotides. Binding is specific for two adenosines, and the length of the phosphate bridge is critical, with four phosphates being optimal [Hilderman et al. (1991) J. Biol. Chem. 266, 6915-6918].
J, Walker   +3 more
openaire   +2 more sources

P1 Receptor Agonists/Antagonists in Clinical Trials - Potential Drug Candidates of the Future

Current Pharmaceutical Design, 2019
Background:Adenosine mediates various physiological and pathological conditions by acting on its four P1 receptors (A1, A2A, A2B and A3 receptors). Omnipresence of P1 receptors and their activation, exert a wide range of biological activities. Thus, its modulation is implicated in various disorders like Parkinson’s disease, asthma, cardiovascular ...
Pobitra, Borah   +3 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy